Vildagliptin CAS NO.274901-16-5

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Vildagliptin is another orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitor after sitagliptin. It was developed by Novartis Pharmaceutical Co., Ltd., Switzerland, 2008 It was approved to be marketed in the European Union in 2012 for the treatment of type 2 diabetes. Diabetes is a chronic metabolic disease, and its prevalence is increasing year by year. Type 2 diabetes is a complex disease that combines multi-gene genetic factors and environmental factors. Dipeptidyl peptidase IV (DPP-IV) inhibitor is a new type of anti-diabetic Chemicalbook disease drug, which promotes the biosynthesis and secretion of insulin, inhibits β cell apoptosis, inhibits the secretion of glucagon, and reduces food intake through induction A variety of mechanisms such as these play a role in lowering blood sugar, and can reverse the deteriorating islet function of diabetic patients while controlling blood sugar, showing a good application prospect. Vildagliptin is a representative drug of dipeptidyl peptidase inhibitors. In clinical studies, whether it is used alone or in combination with metformin and insulin, it has shown good anti-diabetic effects and tolerance. The above information is edited and compiled by Lu Yue of chemicalbook.

Vildagliptin is a selective, competitive and reversible DPP24 inhibitor. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like polypeptide 21 (GLP21) are important hormones for maintaining glucose concentration in the body, and both have incretin effects. The insulin-stimulating effect of GIP in patients with type 2 diabetes is impaired. Only GLP21 can play the role of insulin-stimulating hormone. It promotes the secretion of insulin by acting on the receptor on the pancreatic β cell membrane. GLP21 can also inhibit the secretion of glucagon and inhibit gastric emptying to increase satiety (suppress appetite). DPP24 binds to protein and exists in many tissues, such as kidney, liver, brush border of small intestine membrane, pancreatic duct, lymphocytes, endothelial cells, and it can be quickly inactivated by hydrolyzing the second alanine at the N-terminal of GLP21 . This product inhibits the activity of the enzyme by combining with DPP24 to form a DPP24 complex. It increases the concentration of GLP21 and promotes the production of insulin by pancreatic β cells, while reducing the concentration of glucagon, thereby reducing blood sugar. And it has no significant effect on body weight.